Z01 CP010195-03031 (Z01) | |||
---|---|---|---|
Title | ATBC Study | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Albanes, Demetrius | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $759,338 | Project Dates | 02/01/2002 - N/A |
Fiscal Year | 2008 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Aging (5.0%) Biochemical Epidemiology (45.0%) Cancer (100.0%) Cancer Survivorship (5.0%) Chemoprevention (20.0%) Digestive Diseases (5.0%) Helicobacter Pylori (5.0%) |
Bladder (8.0%) Colon/Rectum (16.0%) Esophagus (2.0%) Head and Neck (3.0%) Kidney Cancer (5.0%) Kidney Disease (5.0%) Larynx (3.0%) Leukemia (4.0%) Lung (20.0%) Lymphoma (2.0%) Non Hodgkins Lymphoma (2.0%) Pancreas (10.0%) Prostate (30.0%) |
||
Research Type | |||
Exogenous Factors in the Origin and Cause of Cancer Interactions of Genes and/or Genetic Polymorphisms with Exogenous and/or Endogenous Factors |
|||
Abstract | |||
The ATBC Study, a project between Finland+s National Public Health Institute (NPHI) and NCI, was conducted to determine whether daily supplementation with a-tocopherol, b-carotene, or both, would reduce the incidence of lung or other cancers. Male smokers between the ages of 50 and 69 were recruited from southwestern Finland between April 1985 and June 1988. A total of 29,133 men were randomly assigned to one of four intervention groups: 50 mg/day a-tocopherol (as dl-a-tocopheryl acetate); 20 mg/day b-carotene; both a-tocopherol and b-carotene; or placebo. They were followed for five to eight years during the trial, until death, or 30 April 1993 when intervention was stopped (median follow-up, 6.1 years). Follow-up for endpoints was continued postintervention. |